PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Cash & equivalents declining -16.72% while CRVO's grows 686.43%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Below half of CRVO's 686.43%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-19.08%
Below half of CRVO's 1186.52%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-14.24%
≥ 1.5x CRVO's -0.29%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
≥ 1.5x CRVO's -1.06%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Below half of CRVO's 107.86%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-4.20%
Less than half of CRVO's -66.89%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Less than half of CRVO's 31868.57%. David Dodd sees fewer expansions in other current obligations.
18.79%
Less than half of CRVO's 1062.56%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Less than half of CRVO's 568.24%. David Dodd sees far fewer liability expansions relative to competitor.
2.42%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-5.90%
Below half CRVO's -47.58%. Michael Burry suspects major net losses or high dividends vs. competitor.
-12.27%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
Below half CRVO's -308.16%. Michael Burry sees potential underperformance in building shareholder capital.
-19.02%
Below half CRVO's 107.86%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
Less than half of CRVO's -1215.21%. David Dodd sees better deleveraging or stronger cash buildup than competitor.